- Home
- SER vs DRRX Comparison
SER vs DRRX Comparison
Compare SER & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- DRRX
- Stock Information
- Founded
- SER 2017
- DRRX 1998
- Country
- SER United States
- DRRX United States
- Employees
- SER N/A
- DRRX N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- DRRX Health Care
- Exchange
- SER Nasdaq
- DRRX Nasdaq
- Market Cap
- SER 46.7M
- DRRX 44.4M
- IPO Year
- SER 2018
- DRRX 2000
- Fundamental
- Price
- SER $6.13
- DRRX $0.85
- Analyst Decision
- SER
- DRRX Buy
- Analyst Count
- SER 0
- DRRX 2
- Target Price
- SER N/A
- DRRX $5.00
- AVG Volume (30 Days)
- SER 37.9K
- DRRX 124.7K
- Earning Date
- SER 11-12-2024
- DRRX 11-13-2024
- Dividend Yield
- SER N/A
- DRRX N/A
- EPS Growth
- SER N/A
- DRRX N/A
- EPS
- SER N/A
- DRRX N/A
- Revenue
- SER $3,157,500.00
- DRRX $8,594,000.00
- Revenue This Year
- SER N/A
- DRRX $54.32
- Revenue Next Year
- SER N/A
- DRRX N/A
- P/E Ratio
- SER N/A
- DRRX N/A
- Revenue Growth
- SER 2454.55
- DRRX N/A
- 52 Week Low
- SER $3.81
- DRRX $0.48
- 52 Week High
- SER $23.18
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- SER 58.82
- DRRX 42.97
- Support Level
- SER $4.15
- DRRX $0.72
- Resistance Level
- SER $6.24
- DRRX $0.83
- Average True Range (ATR)
- SER 0.73
- DRRX 0.08
- MACD
- SER 0.08
- DRRX 0.02
- Stochastic Oscillator
- SER 84.62
- DRRX 52.40
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .